$RYN

Rayonier Inc. REIT Stock 12‑Month Price Target Raised to $26, Implies 21% Upside

Analyst estimates for Rayonier Inc. REIT show its 12-month average price target increased to $26 from $25.83, based on six analysts. Targets range from $23 to $32. Using the Aug. 6 closing price, the update implies about 21% upside. The consensus rating remains “Buy” with 2 Buys, 4 Holds, and 0 Sells.

Original reporting
Published Aug 7, 2026, 11:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rayonier Inc. REIT Stock 12‑Month Price Target Raised to $26, Implies 21% Upside — source image
Decision brief

The 30-second read

$RYNBullishLow
01

Why it matters

The only actionable signal is sentiment from analyst target revision (average target up to $26) and the implied upside versus the Aug. 6 close; no new company-specific operational or financial disclosure is provided.

02

Market read

Traders may treat this as a mild bullish sentiment update, but it lacks the detail needed for a high-conviction trade.

03

What to watch

The article does not specify the reason for the target increase, nor whether any analyst changed earnings estimates, so traders should verify the underlying assumptions before acting.

Relevance 4/10Novelty 4/10Timing: post-close context around the Aug. 6 reference price target update

Background

The piece summarizes FactSet-based analyst consensus for Rayonier Inc. REIT, focusing on the updated 12-month price target and rating distribution.

Company-level read

Ticker impact

$RYNBullishMedium confidence
Context

Rayonier Inc. REIT’s 12-month average analyst price target rose from $25.83 to $26, implying about 21% upside from the Aug. 6 close.

Expected impact

Likely modest near-term support from sentiment/positioning, with limited follow-through unless additional upgrades or new fundamentals emerge.

Evidence & confidence

The article only reports analyst target revisions and consensus mix (Buy/Hold), with no new guidance, earnings, or operational catalyst disclosed.

Market effects

Minimal. Analyst target changes for a single REIT do not materially reset sector fundamentals in the text.

None indicated.

None indicated.

Counterpoint

A raised target can reflect model assumptions rather than improved fundamentals, so the stock may not re-rate if the underlying thesis is unchanged.

Key entities

  • Rayonier Inc. REIT

    Subject of the article, with consensus 12-month price target raised to $26 and Buy/Hold mix unchanged at 6 analysts.

Related articles

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$BWAMed

Why Is BorgWarner (BWA) Expanding Its Edge In China And EV Systems?

BorgWarner (NYSE:BWA) said it won new variable cam timing system contracts in Europe and China, including a conquest award, and that the wins expand positions with existing customers and replace a competitor on a China program. It also received awards for high voltage inverters and integrated drive modules for hybrid and EV platforms, which it said add to backlog.

$AVAVMedAI 8/10

Bloomberg: US to purchase anti-drone lasers for $400 million

Bloomberg reports the Pentagon will buy laser-based counter-drone systems from AeroVironment Inc. in a deal valued at at least $400 million. The contract is expected to supply the Army with dozens of Locust systems, described as an AI-enabled laser system for tracking and disabling small and medium UAVs. AeroVironment shares rose 8.1% intraday, according to the report.